Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05626738
Other study ID # Endorail
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 25, 2023
Est. completion date July 24, 2023

Study information

Verified date July 2023
Source Endostart srl
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Patients with long lasting colonoscopy are characterized by higher risk of incompletion. Endorail is an accessory for colonoscopy aimed at facilitating progression of the endoscope in the large intestine. Endorail works as a magnetic anchor that is able to guide the colonoscope and to straighten colon curves and loops. The aim of this study is to test the safety and efficacy of Endorail in ensuring that incompletion rate in long-lasting colonoscopies is lower than the 10% threshold. Outpatients of either sex aged between 22-75 years undergoing elective diagnostic or surveillance colonoscopy with caecal intubation time greater than 10 minutes will take part in the study. The primary efficacy endpoint is the percentage minor or equal to 10% of incomplete long-lasting colonoscopies. The primary safety endpoints are the absence of device-related serious adverse events and the evaluation of the equality or reduction of the adverse events rates compared to diagnostic colonoscopies without Endorail.


Description:

Patients with long lasting colonoscopy are characterized by higher risk of incompletion. A colonoscopy can be defined as incomplete when the endoscopist cannot reach the caecum. Caecal intubation is one of the main goals of colonoscopy and represents a diagnostic quality indicator. International guidelines recommend caecal intubation rates ≥90% for all colonoscopies in daily clinical practice. Reported incomplete colonoscopy rates range from 4% to 25%. Caecal intubation fails in 4-10% of cases in tertiary referred centres, instead in national surveys colonoscopies are incomplete in 10-25% of cases. Endorail is a medical device intended to facilitate the positioning of a standard colonoscope. Endorail is a colonoscopy add-on device that works as a magnetic anchor able to guide the colonoscope and to straighten colon curves and loops. Endorail is composed by the following two CE marked medical devices: Endorail Set and Endorail System. Endorail Set consists of the Endorail Balloon Guide, The Endorail Solution Syringe, The Endorail Powder and the Spike. Endorail System consists of the Endorail Handpiece and the Endorail Cart. The aim of this study is to test the safety and efficacy of the Endorail in ensuring that incompletion rate in long-lasting colonoscopies is lower than the 10% threshold. Outpatients of either sex aged between 22-75 years, undergoing elective colonoscopy for diagnostic or surveillance colonoscopy, who have signed a written informed consent and presenting caecal intubation time greater than 10 minutes, will take part in the study. The study plan will include a screening/baseline/treatment visit (Visit 1/Day 1), during which colonoscopy with the investigational medical device Endorail will be performed and a phone follow-up visit (Visit 2), scheduled at 7 (± 1) day after treatment with the investigational medical device Endorail. The primary efficacy endpoint is the percentage minor or equal to 10% of incomplete long-lasting colonoscopies The primary safety endpoints are: - The absence of device-related serious adverse events. AND - The evaluation of the equality or reduction of the adverse events rates compared to diagnostic colonoscopies without Endorail.


Recruitment information / eligibility

Status Completed
Enrollment 38
Est. completion date July 24, 2023
Est. primary completion date May 24, 2023
Accepts healthy volunteers No
Gender All
Age group 22 Years to 75 Years
Eligibility Inclusion Criteria: 1. Patients of both sexes aged between 22 - 75 years (inclusive); 2. Outpatients undergoing long-lasting diagnostic and surveillance colonoscopy; long-lasting colonoscopy is defined as follows: colonoscopy completion (caecal intubation) not achieved after 10 minutes from endoscope insertion through the anal canal; 3. Patients have given a written informed consent for participation in the study at the time of enrolment or before; 4. Patients able to understand the full nature and the purpose of the investigation, including possible risks and side effects, able to cooperate with the Investigator and to comply with the requirements of the entire investigation based on Investigator's judgement. Exclusion Criteria: 1. Body mass index (BMI) > 30 kg/m2; 2. Outpatients undergoing colonoscopy for colorectal cancer screening or therapeutic indication; 3. Patients in class >2 physical status of the classification system of American Society of Anaesthesiologists; 4. Any contraindications to colonoscopy; 5. Any contraindications to sedation; 6. Known allergy or hypersensitivity to any of the elements of the Endorail Set (e.g.: iron); 7. Patients with permanently or semi-permanently implanted medical devices, (e.g. orthopedic implants, trauma fixation devices, cardiac pacemakers, implantable cardioverter defibrillator, drug pumps, neurostimulators, vascular stents, cochlear implants, aneurysm clip); 8. Presence of dense diverticulosis 9. Presence of diverticulitis 10. Presence of ferromagnetic foreign body; 11. Presence of large abdominal hernias; 12. Presence of severe thrombocytopenia; 13. Presence of severe granulocytopenia; 14. Presence of severe coagulopathy; 15. Presence of peritonitis; 16. Presence of colonic wall ischemia or necrosis or injured mucosa; 17. Presence of peritoneal carcinomatosis; 18. Boston Bowel Preparation Scale <2 in at least one of the colonic segments; 19. Presence of obstructing masses and strictures of the colon; 20. History of total or subtotal colectomy. 21. Presence of angulated and fixed colon curves; 22. Pregnant or breast-feeding women; 23. Patient unable to provide the signed informed consent, uncooperative patient or patient unlikely to comply with the protocol or unable to understand the nature, scope and possible consequences of the study; 24. Presence of any other reason that, in the opinion of the investigator, prevents the subject from participating in the study or compromises the subject safety 25. Concomitant participation in other clinical investigations or participation in the evaluation of any investigational product/device in the 30 days before this study or previous participation in the same investigation; 26. Urgent colonoscopy.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
ENDORAIL
In case caecal intubation time is longer than 10 minutes, the balloon catheter is inserted in the tool channel, advanced beyond the colonoscope tip and filled with Ferromagnetic Fluid. By applying the Endorail Handpiece over the patient abdomen, the balloon can be magnetically anchored. The anchored balloon guide allows to straighten the scope and the colon itself. The colonoscope can thus be easily moved back and forward along the anchored guide to facilitate colonoscope positioning and colonoscopy completion. Afterward, Endorail is removed and the straightened colonoscope can be easily pushed forward to achieve colonoscopy completion according to standard endoscopic technique.

Locations

Country Name City State
Belgium University Hospitals Leuven
Germany Gastrozentrum Lippe
Italy Humanitas Milano

Sponsors (1)

Lead Sponsor Collaborator
Endostart srl

Countries where clinical trial is conducted

Belgium,  Germany,  Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluation of Endorail efficacy The percentage minor or equal to 10% of incomplete long-lasting colonoscopies (colonoscopy is defined completed when caecal intubation is achieved) day 1
Primary Evaluation of Endorail safety The absence of device-related serious adverse events will be collected during the treatment day 1
Primary Evaluation of Endorail safety The absence of device-related serious adverse events will be collected through phone call after 7 days of procedure day 7
See also
  Status Clinical Trial Phase
Completed NCT04101097 - Training and Validation of Models of Factors to Predict Inadequate Bowel Preparation Colonoscopy
Completed NCT03247595 - Testing How Well Magnesium Citrate Capsules Work as Preparation for a Colonoscopy N/A
Completed NCT04214301 - An Open-Label Preference Evaluation of BLI800 Phase 4
Withdrawn NCT05754255 - Comparison of High-flow Oxygen With or Without Nasal Positive Airway Pressure (PAP) During Propofol Sedation for Colonoscopy in an Ambulatory Surgical Center N/A
Recruiting NCT02484105 - Comforting Conversation During Colonoscopy: A Trial on Patient Satisfaction Phase 4
Active, not recruiting NCT02264249 - Residual Gastric Volume in Same Day Versus Split Dose and Evening Before Bowel Preparation N/A
Terminated NCT01978509 - The Affect of Low-Volume Bowel Preparation for Hospitalized Patients Colonoscopies N/A
Completed NCT01964417 - The Comparative Study Between Bowel Preparation Method Phase 3
Recruiting NCT01685970 - Comparison of Same-day 2 Sachets Picosulfate Versus High Volume PEG for Afternoon Colonoscopy Phase 3
Completed NCT01518790 - Short Course, Single-dose PEG 3350 for Colonoscopy Prep in Children N/A
Recruiting NCT00748293 - Achievement of Better Examinee Compliance on Colon Cleansing Using Commercialized Low-Residue Diet N/A
Completed NCT00779649 - MoviPrep® Versus HalfLytely®, Low-VolUme PEG Solutions for Colon Cleansing: An InvesTigator-blindEd, Randomized, Trial Phase 4
Completed NCT00671177 - Clinical Evaluation of Water Immersion Colonoscopy Insertion Technique N/A
Completed NCT00380497 - Pico-Salax Versus Poly-Ethylene Glycol for Bowel Cleanout Before Colonoscopy in Children Phase 4
Recruiting NCT00160823 - Impact of a Self-Administered Information Leaflet on Adequacy of Colonic Cleansing for in-Hospital Patients Phase 3
Completed NCT00314418 - Patient Position and Impact on Colonoscopy Time N/A
Completed NCT00390598 - PEG Solution (Laxabon®) 4L Versus Senna Glycoside (Pursennid® Ex-Lax) 36mg and PEG Solution (Laxabon®) 2L for Large Bowel Cleansing Prior to Colonoscopy Phase 2/Phase 3
Completed NCT00209573 - A Study of AQUAVAN® Injection Versus Midazolam HCl for Sedation in Patients Undergoing Elective Colonoscopy Phase 3
Completed NCT00427089 - Comparison of 2L NRL994 With NaP Preparation in Colon Cleansing Prior to Colonoscopies for Colon Tumor Screening Phase 3
Completed NCT05823350 - The Effect of Abdominal Massage on Pain and Distention After Colonoscopy N/A